Dr Reddy’s Lab: R&D driving growth - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

Dr Reddy’s Lab: R&D driving growth

Jun 24, 2003

Continuing with our series of articles evaluating the business structure of major pharma companies, consider Dr. Reddy’s Laboratories (DRL) in this article. DRL is one of India’s fastest growing pharma companies. The foresightedness in recognizing generics opportunity in developed markets and initiatives like spearheading basic pharma research in the country demonstrates management vision. The company is fast emerging as a speciality pharma company. DRL’s new drug discovery research initiatives have resulted in the company having the most enviable NCE pipeline in the domestic industry.

Geographical distribution of revenues (%)
Region FY01 FY02 FY03
India 54 39 36
USA 15 34 32
Europe 2 2 8
Russia 7 8 9
RoW 22 17 15

DRL derives 64% of its revenues from exports. There has been a sharp increase in contribution from the US. This has been possible due to the company’s policy of challenging existing drug patents in USA through Para 4 ANDA filings and launching generic version of the same at a lower cost. This has helped DRL reduce its dependence on the Indian market, which is characterised by intense competition and lack of pricing power. With the acquisition of BMS and Meridian in FY03 in the UK, DRL has further consolidated its presence in Europe.

Revenue mix (%)
  FY01 FY02 FY03
Bulk drugs 44 31 35
Branded formulation 50 36 38
Generics 3 27 24
Others 3 6 3

Branded formulations contributed 38% of DRL’s total revenues in FY03, with the domestic market contributing 24% of sales. The company has a major presence in the pain management, gastro intestinal and cardiovascular therapeutic segments. For many years, ‘Nise’ had been DRL’s power brand contributing 15% of domestic branded sales. However, with safety concerns being raised, the company has decided to discontinue production of this brand.

Financial overview
  FY01 FY02 FY03
Revenues (Rs m) 9,127 15,211 15,136
PAT (Rs m) 1,445 4,597 3,921
OPM (%) 26.6 31.5 28.3
NPM (%) 15.8 30.2 25.9
R & D (% of Revenues) 4.6 6.4 7.6

DRL has been able to successfully challenge existing patents due to the company’s increased thrust on research and development. R&D investments as a percentage of net sales have gone up from 4.6% in FY01 to 7.6% in FY03. In FY03, DRL has filed 14 Abbreviated New Drug Applications (ANDAs) of which 10 were Para 4 filings. Thus, the total number of ANDAs pending for US FDA approval stands at 23. Recently, DRL had won a patent case for the launch of ‘Amlodipine Maleate’, a generic version of Pfizer’s patented drug ‘Norvasc’. Pfizer has appealed against the order, and the case in pending with the higher courts. If DRL wins the case, it will be able to generate profits to the tune of US$ 98 m, which is higher than its FY03 profits of US$ 74m.

  • More on pharma R&D

    DRL has also started developing New Chemical Entities (NCE), which is a molecule that could after clinical trials be used for curing a disease. The company licenses out the NCEs to foreign companies for conducting clinical trails and receives upfront and milestone payments for the same. In FY02, DRL received upfront and milestone payments (Rs 389 m) in respect of two NCEs DRF-2725 and DRF-4158 licensed to Novo Nordisk and Novartis respectively.

    Dr Reddy's NCE pipeline
    Therapeutic segment Stage of development
    Pre clinical stage Clinical trials
    Phase 1 Phase 2
    Diabetes - - DRF 2593
    Metabolic disorder DRF 4832, DRF 10945 - -
    Cancer DRF1644 DRF 1042 -
    Bacterial infection DRF 11057 - -

    However, DRL’s research has had its share of failures as well. Clinical trials in respect of two of the three molecules licensed have been discontinued. Novo Nordisk terminated clinical trials for the NCE DRF-2725, while Novartis AG discontinued further development of DRF-4158. This has come as a major setback to DRL, as it would not be receiving any further milestone payments in respect of these two molecules. NCE research and new drug development being a high-risk activity, DRL could show volatility in performance.

    Apart from R&D failure risks, with DRL aggressively challenging existing patents, the legal expenses of the company could record a sharp rise. Moreover, the discontinuance of its leading brand ‘Nise’ could have a marginal effect on the performance of the company.

    The stock currently trades at Rs 1,058 implying a P/E multiple of 16.6x annualised 1QFY04 earnings. DRL’s strategy of increasing R&D expenditure indicates the company’s preparedness to face the future. In the near term, due to the high-risk ventures that DRL has undertaken, the performance of the company may be affected. However, for the long term, prospects of the company are bright.

  • Equitymaster requests your view! Post a comment on "Dr Reddy’s Lab: R&D driving growth ". Click here!


    More Views on News

    Sorry! There are no related views on news for this company/sector.

    Most Popular

    A Critical Update on the Market (Fast Profits Daily)

    Mar 30, 2021

    In this video, I'll tell you why I am recommending caution in the market at this time.

    My Recent Recommendation Will Profit from the Global Supply Chain Crisis (Profit Hunter)

    Mar 31, 2021

    A tiny chemical company, started in the Licence Raj era, is a great example of a new wealth creating opportunity.

    My Stock Trading Strategy (Fast Profits Daily)

    Mar 31, 2021

    In this video I'll show you exactly how I go about picking stocks for trading.

    What You Need to Find Hundred Baggers (Profit Hunter)

    Mar 30, 2021

    100 baggers of the last decade share this common trait. Here's how to use it to nail future multibaggers.


    India's #1 Trader
    Reveals His Secrets

    Secret To Increasing Your Trading Profits Today
    Get this Special Report,
    The Secret to Increasing Your Trading Profits Today, Now!
    We will never sell or rent your email id.
    Please read our Terms


    Apr 1, 2015 (Close)


    • Track your investment in RANBAXY LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks